The tricuspid valve is anatomically complex. It’s often called the “forgotten valve” because of its position in the back of ...

Southlake is the second hospital in Ontario and one of the first four hospitals in Canada to use this technology, after ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

As tools become more precise and non-invasive, doctors are able to diagnose and treat heart conditions with greater accuracy ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

The U.S. Food and Drug Administration (FDA) has approved the EVOQUE tricuspid valve replacement system for the treatment of tricuspid regurgitation (TR). According to an Edwards press release, “it is ...

He then explores a randomized trial that investigates the effects of implantable cardioverter-defibrillator (ICD) leads on the tricuspid valve and right ventricle. Finally, Dr. Eagle discusses the ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

For some patients with atrial fibrillation (Afib, AF) and valvular heart disease (VHD), direct oral anticoagulants (DOACs) ...

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...